.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Once-daily regimen may effectively lower IOP

April 1, 2004

Sarasota, FL-Data from three clinical trials show that Travatan/Timolol Fixed Combination (TTFC), Alcon's investigational new drug to treat glaucoma, is a safe alternative to the two single compounds dosed concomitantly, the company says.